{"groups":[{"description":"Participants began oral administration of ruxolitinib at 5 mg twice a day (BID); if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID. Participants did receive prednisone 2.5 mg/kg per day orally (PO) or methylprednisolone 2.0 mg/kg per day IV.","id":"FG000","title":"Ruxolitinib in Combination With Corticosteroids"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"23"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Progressive Disease of GVHD"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Relapse of Underlying Malignancy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by participant"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Includes 2 participants who discontinued ruxolitinib treatment because of clinical improvement"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Participants were transferred to commercial product."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"71"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"71"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study was conducted at 26 study centers in the United States."}